ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy

Inclusion Criteria:

• Pathogenic or likely pathogenic mutation in BAG3

• Medical history of diagnosis of DCM

• Stable combination of HF SoC medications

• Adequate acoustic windows for echocardiography

• LVEF > 15% and ≤ 45% at Screening by echocardiography

• Diagnosis of chronic HF for at least 3 months

• NYHA Class I/II/III at Screening

Exclusion Criteria:

• Presence of antibodies to AAV9

• Presence of a pathogenic or likely pathogenic variant in another gene where thatother gene is authoritatively recognized as causal for DCM

• Decompensated HF

• Cardiac ventricular arrhythmia that requires treatment

• History of untreated clinically significant valve disease or a Screeningconfirmation of severe aortic stenosis, severe mitral stenosis, moderate or severeaortic insufficiency or severe mitral insufficiency

• NYHA Class IV

• History of substance abuse that could contribute to cardiac dysfunction

Note: Other inclusion and exclusion criteria may apply.